Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280082 | 0.87 | MAPT (0.60) | MEN1ALDH1A1HPGDKMT2AATM | |
| SCHEMBL26246771 | 0.77 | RXRA (0.56) | ALDH1A1HPGDKMT2ARXRARXRB | |
| SCHEMBL420401 | 0.77 | ALOX15 (0.68) | RXRARXRBHDAC1HDAC2MRGPRX4 | |
| SCHEMBL25695882 | 0.76 | L3MBTL1 (0.50) | MEN1ALDH1A1HPGDKMT2AATM | |
| SCHEMBL5286009 | 0.76 | L3MBTL1 (0.56) | ALDH1A1RXRARXRBMAPTL3MBTL1 | |
| SCHEMBL5285624 | 0.74 | MRGPRX4 (0.58) | ALDH1A1MRGPRX4L3MBTL1PTGER4FFAR4 | |
| SCHEMBL10784303 | 0.72 | MAPT (0.64) | MEN1ALDH1A1HPGDKMT2AGAA | |
| SCHEMBL31226122 | 0.72 | ACMSD (0.43) | HPGDGAAHDAC1 | |
| SCHEMBL31225490 | 0.72 | SMN1; SMN2 (0.55) | MEN1ALDH1A1KMT2AGAA | |
| SCHEMBL404889 | 0.72 | KMT2A (0.54) | MEN1ALDH1A1KMT2AGAAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | MEN1 2853/4885ALDH1A1 2972/4885HPGD 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.